Invivyd (NASDAQ:IVVD) Insider Jill Andersen Sells 32,771 Shares

Invivyd, Inc. (NASDAQ:IVVD) insider Jill Andersen sold 32,771 shares of the stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $1.54, for a total value of $50,467.34. Following the transaction, the insider owned 216,675 shares in the company, valued at $333,679.50. This trade represents a 13.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Jill Andersen also recently made the following trade(s):

• On Wednesday, February 18th, Jill Andersen sold 34,939 shares of Invivyd stock. The shares were sold at an average price of $1.58, for a total value of $55,203.62.

Invivyd Price Performance

Shares of IVVD stock opened at $1.65 on Thursday. Invivyd, Inc. has a 1-year low of $0.46 and a 1-year high of $3.07. The firm’s 50-day simple moving average is $2.19 and its 200-day simple moving average is $1.75. The firm has a market cap of $384.65 million, a P/E ratio of -3.51 and a beta of 0.60.

Key Stories Impacting Invivyd

Here are the key news stories impacting Invivyd this week:

• Negative Sentiment: Jill Andersen sold 34,939 shares on Feb. 18 at an average price of $1.58 (≈$55.2k); her holdings fell ~16.1% to 181,736 shares. SEC Filing
• Negative Sentiment: Jill Andersen sold 32,771 shares on Feb. 17 at $1.54 (≈$50.5k); that trade reduced her position by ~13.1%. SEC Filing
• Negative Sentiment: Timothy Edward Lee sold 20,964 shares on Feb. 18 at $1.58 (≈$33.1k); his stake declined ~15.1% to 117,717 shares. SEC Filing
• Negative Sentiment: Timothy Edward Lee sold 19,663 shares on Feb. 17 at $1.54 (≈$30.3k); his ownership fell ~12.4%. SEC Filing
• Negative Sentiment: William E. Duke (CFO) sold 20,964 shares on Feb. 18 at $1.58 (≈$33.1k); his stake dropped ~16.3% to 107,717 shares. SEC Filing
• Negative Sentiment: William E. Duke sold 19,663 shares on Feb. 17 at $1.54 (≈$30.3k); his position fell ~13.3%. SEC Filing
• Negative Sentiment: Julie Green sold 20,964 shares on Feb. 18 at $1.58 (≈$33.1k); her holdings declined ~16.3% to 107,717 shares. SEC Filing
• Negative Sentiment: Julie Green sold 19,663 shares on Feb. 17 at $1.54 (≈$30.3k); that trade lowered her stake ~13.3%. SEC Filing
• Negative Sentiment: Robert D. Allen III sold 19,392 shares on Feb. 18 at $1.58 (≈$30.6k); his holdings fell ~14.5% to 114,487 shares. SEC Filing
• Negative Sentiment: Robert D. Allen III sold 18,189 shares on Feb. 17 at $1.54 (≈$28.0k); his position declined ~12.0%. SEC Filing

Institutional Trading of Invivyd

Large investors have recently added to or reduced their stakes in the business. Janus Henderson Group PLC grew its position in Invivyd by 28.2% in the 4th quarter. Janus Henderson Group PLC now owns 32,543,142 shares of the company’s stock valued at $80,870,000 after buying an additional 7,160,065 shares in the last quarter. Perceptive Advisors LLC acquired a new position in shares of Invivyd during the fourth quarter valued at approximately $53,809,000. BVF Inc. IL bought a new stake in Invivyd during the fourth quarter worth approximately $48,227,000. RA Capital Management L.P. acquired a new stake in Invivyd in the third quarter worth approximately $18,831,000. Finally, ADAR1 Capital Management LLC acquired a new position in shares of Invivyd during the 3rd quarter valued at $8,108,000. 70.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages recently commented on IVVD. BTIG Research reiterated a “buy” rating on shares of Invivyd in a report on Wednesday, January 21st. Zacks Research upgraded Invivyd from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 13th. D. Boral Capital restated a “hold” rating on shares of Invivyd in a research note on Tuesday, November 25th. HC Wainwright upped their price target on shares of Invivyd from $5.00 to $10.00 and gave the company a “buy” rating in a report on Friday, October 31st. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Invivyd in a report on Monday, December 29th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $8.00.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.